Moderna (NASDAQ:MRNA) Releases Quarterly Earnings Results, Beats Estimates By $0.52 EPS

Moderna (NASDAQ:MRNA) released its quarterly earnings results on Thursday. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52, Briefing.com reports. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the business posted $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year.

Moderna Trading Down 0.5 %

Shares of NASDAQ:MRNA traded down $0.59 during midday trading on Friday, reaching $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna has a 1-year low of $62.55 and a 1-year high of $142.79. The firm has a market cap of $47.86 billion, a price-to-earnings ratio of -10.07 and a beta of 1.57. The company has a fifty day simple moving average of $105.05 and a two-hundred day simple moving average of $94.37.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MRNA shares. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. HSBC reissued a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Canaccord Genuity Group lifted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $129.55.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the transaction, the director now owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the sale, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock worth $14,822,576 in the last quarter. 15.70% of the stock is owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.